Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Organon (OGN) reached $10.84 at the closing of the latest trading day, reflecting a -1.54% change compared to its last close.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN) reached $10.35 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
OGN vs. HQY: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)
Organon & Co.'s shrinking revenues, heavy debt, and slashed dividend make it an unattractive investment despite its low valuation metrics. The Established Brands division is in decline, and new products like Emgality and VTAMA are not offsetting losses from older drugs. Women's Health and Biosimilars show some growth, but not enough to reverse the overall negative trend or justify optimism.
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Jennifer Halchak - Corporate Participant Juan Camilo Arjona Ferreira - Executive VP, Head of Research & Development and Chief Medical Officer Kevin Ali - CEO & Director Matthew M. Walsh - Executive VP & CFO Conference Call Participants Alexandra Doering von Riesemann - Piper Sandler & Co., Research Division Ethan Harris Brown - JPMorgan Chase & Co, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Michael Thomas Nedelcovych - TD Cowen, Research Division Terence C.
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Beats Q2 Earnings and Revenue Estimates
Organon (OGN) came out with quarterly earnings of $1 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $1.12 per share a year ago.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Organon (OGN) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Organon (OGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Organon (OGN) closed at $9.7, indicating a -3.39% shift from the previous trading day.
